CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
18 05 2023
Historique:
accepted: 12 01 2023
received: 05 01 2022
medline: 22 5 2023
pubmed: 18 2 2023
entrez: 17 2 2023
Statut: ppublish

Résumé

Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution are yet to be fully elucidated. Previously, we identified a critical role for combined constitutive JAK/STAT and aberrant NF-κB proinflammatory signaling in MF development. Using single-cell transcriptional and cytokine-secretion studies of primary cells from patients with MF and the human MPLW515L (hMPLW515L) murine model of MF, we extend our previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. Hematopoietic stem/progenitor cells from patients with MF are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to an exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L-adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway among patients with MF.

Identifiants

pubmed: 36800567
pii: 494598
doi: 10.1182/blood.2022015418
pmc: PMC10273167
doi:

Substances chimiques

Cytokines 0
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2508-2519

Subventions

Organisme : NCI NIH HHS
ID : P01 CA108671
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIBIB NIH HHS
ID : R44 EB023777
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
J Clin Oncol. 2011 Apr 1;29(10):1356-63
pubmed: 21300928
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Matrix Biol. 2018 Aug;68-69:106-121
pubmed: 29196207
J Leukoc Biol. 2002 Nov;72(5):847-55
pubmed: 12429706
Hematol Oncol Clin North Am. 2010 Apr;24(2):343-59
pubmed: 20359630
Blood Adv. 2019 Jan 22;3(2):122-131
pubmed: 30647074
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Leukemia. 2021 Feb;35(2):454-467
pubmed: 32472085
PLoS One. 2019 May 9;14(5):e0216810
pubmed: 31071164
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Vaccines (Basel). 2016 Jun 24;4(3):
pubmed: 27348007
Cell. 2015 May 21;161(5):1202-1214
pubmed: 26000488
Rev Bras Hematol Hemoter. 2014 Sep-Oct;36(5):322-8
pubmed: 25305163
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Genesis. 2013 Aug;51(8):587-95
pubmed: 23650205
Nat Protoc. 2012 Mar 15;7(4):670-85
pubmed: 22422314
Blood. 2005 Jan 15;105(2):464-73
pubmed: 15454487
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
Cancer Res. 2017 Jan 15;77(2):303-311
pubmed: 27872094
Haematologica. 2017 Jan;102(1):7-17
pubmed: 27909216
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 2014 Aug 7;512(7512):78-81
pubmed: 25043017
Anal Chem. 2013 Feb 19;85(4):2548-56
pubmed: 23339603
J Exp Med. 2016 Aug 22;213(9):1723-40
pubmed: 27481130
Blood. 2020 Oct 29;136(18):2051-2064
pubmed: 32726410
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Hematol Oncol. 2017 Feb 22;10(1):55
pubmed: 28228106
Blood. 2011 Dec 8;118(24):6392-8
pubmed: 21860020
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Haematologica. 2005 Aug;90(8):1128-32
pubmed: 16079113
Front Oncol. 2022 Mar 22;12:853484
pubmed: 35392239
Blood. 2002 Nov 15;100(10):3495-503
pubmed: 12393681
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nucleic Acids Res. 2019 Feb 20;47(3):e16
pubmed: 30462277
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L127-L136
pubmed: 28860143
Cell Stem Cell. 2016 Nov 3;19(5):613-627
pubmed: 27666011
JCI Insight. 2017 Apr 6;2(7):e90932
pubmed: 28405618
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Cell. 2016 Dec 15;167(7):1897
pubmed: 27984737
Blood. 2015 May 14;125(20):3144-52
pubmed: 25810490
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell Rep. 2021 Jul 13;36(2):109386
pubmed: 34260914
J Immunol. 2004 Sep 15;173(6):4197-206
pubmed: 15356171
Nat Commun. 2022 Sep 13;13(1):5346
pubmed: 36100613
Cytokine Growth Factor Rev. 2013 Apr;24(2):133-45
pubmed: 23415024
Leukemia. 2019 Aug;33(8):1978-1995
pubmed: 30718771
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Leukemia. 2017 Sep;31(9):1962-1974
pubmed: 28008177
Cancer Discov. 2015 Mar;5(3):316-31
pubmed: 25572172
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Cell Stem Cell. 2014 Apr 3;14(4):445-459
pubmed: 24561084
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4757-4762
pubmed: 28424250
Blood. 2016 Jun 30;127(26):3410-23
pubmed: 27081096
Mol Cell. 2019 Mar 21;73(6):1292-1305.e8
pubmed: 30765193
JAMA Oncol. 2015 Apr;1(1):97-105
pubmed: 26182311
Nat Cell Biol. 2017 Jun;19(6):677-688
pubmed: 28481328
Cell Stem Cell. 2013 Sep 5;13(3):285-99
pubmed: 23850243
Mol Biol Evol. 1999 Feb;16(2):180-93
pubmed: 10028286
Cancer Cell. 2018 Apr 9;33(4):785-787
pubmed: 29634952
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8
pubmed: 33301706
Nat Methods. 2017 Apr;14(4):395-398
pubmed: 28192419
Cell Stem Cell. 2018 Aug 02;23(2):308-309
pubmed: 30075132
Front Immunol. 2021 Jun 01;12:683401
pubmed: 34140953
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187

Auteurs

Andrew J Dunbar (AJ)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.

Dongjoo Kim (D)

Department of Biomedical Engineering, Yale University, New Haven, CT.

Min Lu (M)

Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.
Division of Hematology/Oncology, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Mirko Farina (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Blood Diseases and Bone Marrow Transplantation Unit, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Robert L Bowman (RL)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Julie L Yang (JL)

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.

Young Park (Y)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Abdul Karzai (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Wenbin Xiao (W)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Zach Zaroogian (Z)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Kavi O'Connor (K)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Shoron Mowla (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Francesca Gobbo (F)

Department of Veterinary Medical Sciences, University of Bologna, Italy.

Paola Verachi (P)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.

Fabrizio Martelli (F)

Department of Technology and Health, Istituto Superiore di Sanità, Rome, Italy.

Giuseppe Sarli (G)

Department of Veterinary Medical Sciences, University of Bologna, Italy.

Lijuan Xia (L)

Division of Hematology/Oncology, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Nada Elmansy (N)

Division of Hematology/Oncology, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Maria Kleppe (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Zhuo Chen (Z)

Department of Biomedical Engineering, Yale University, New Haven, CT.

Yang Xiao (Y)

Department of Biomedical Engineering, Yale University, New Haven, CT.

Erin McGovern (E)

Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.

Jenna Snyder (J)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Aishwarya Krishnan (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Corrine Hill (C)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Keith Cordner (K)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Anouar Zouak (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Mohamed E Salama (ME)

Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.
Department of Pathology, Mayo Clinic School of Medicine, Rochester, MN.

Jayden Yohai (J)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Eric Tucker (E)

IsoPlexis Corporation, Branford, CT.

Jonathan Chen (J)

IsoPlexis Corporation, Branford, CT.

Jing Zhou (J)

IsoPlexis Corporation, Branford, CT.

Timothy McConnell (T)

IsoPlexis Corporation, Branford, CT.

Anna R Migliaccio (AR)

Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.
Altius Institute for Biomedical Sciences, Seattle, WA.
Unit of Microscopic and Ultrastructural Anatomy, Università Campus Bio-Medico di Roma, Rome, Italy.

Richard Koche (R)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.

Raajit Rampal (R)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.

Rong Fan (R)

Department of Biomedical Engineering, Yale University, New Haven, CT.

Ross L Levine (RL)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.

Ronald Hoffman (R)

Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.
Division of Hematology/Oncology, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH